The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Hope Funds for Cancer Research announce James D. Watson Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE HOPE FUNDS FOR CANCER RESEARCH announced the creation of the James D. Watson Award, with Nobel laureate James Watson being the first recipient.

The award honors Watson for his contributions to the field of biology and cancer research and will be awarded to scientists who make comparable seminal discoveries. The award will be presented at the organization’s annual awards dinner on April 24 in New York City.

Watson is best known as a co-discoverer of the structure of DNA in 1953 with Francis Crick. He was awarded the 1962 Nobel Prize in Physiology or Medicine along with Crick and Maurice Wilkins.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalRegulatory NewsTrials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
By Edison T. Liu
Sponsored

Why both somatic and germline genomic profiling are essential for precision oncology

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 
By Heather Hampel and David W. Craig
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account